Lipid encapsulated cisplatin (Allarity Therapeutics /LiPlasome Pharma)

N/A

Report date: 2024/07/03 21:31:43

Base Information

Drug NameLipid encapsulated cisplatin (Allarity Therapeutics /LiPlasome Pharma)
Drug Alias NameLiPlaCisLiposomal formulation of cisplatin (Allarity Therapeutics /LiPlasome Pharma)Liposomal formulation of Cisplatinum (Allarity Therapeutics /LiPlasome Pharma)
ClassificationSmall molecules
Mechanisms of ActionDNA cross linking agentsDNA synthesis inhibitors
TargetsDNA
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsSkin Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryDenmark
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesLiPlasome Pharma ApS
China Registration ClassN/A

Develop Information

Active CompaniesMedical Prognosis Institute AsOncology Venture A/SAllarity Therapeutics A/S
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic NeoplasmsSkin Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A